医学
叙述性评论
皮肤病科
贾纳斯激酶
评论文章
梅德林
酪氨酸激酶
激酶
鲁索利替尼
重症监护医学
叙述的
系统回顾
生物信息学
Janus激酶抑制剂
癌症
药理学
Janus激酶2
内科学
作者
Manabu Ohyama,M. Fukuyama,Reina Hayakawa,Misaki Kinoshita‐Ise
出处
期刊:日本臨床免疫学会会誌
日期:2026-03-27
卷期号:: 1-12
被引量:2
标识
DOI:10.1080/25785826.2026.2647503
摘要
Alopecia areata (AA) is a common autoimmune, non-scarring hair loss disease in which anagen hair follicles are predominantly affected. Typically, from a single to multiple and round to oval patchy hair loss is observed in AA with a tendency for spontaneous regression; however, total scalp or whole-body hair loss can be seen in severe cases. 'IFN-γ-IL-15 cytokine loop' existing between autoreactive cytotoxic T cells and hair follicle epithelial cells underlies AA intractability, leading to the development of Janus kinase inhibitors (JAKis) inhibiting the downstream signaling pathways as remedies for severe AA. JAKis were shown to be effective and tolerable in clinical studies and now, baricitinib and ritlecitinib have been used for severe AA in Japan. Despite the fact that these medications can achieve clinically meaningful hair regrowth in around 30%-40% of treated patients, nearly 30% of patients have been found to be non-responders both in post-hoc analyses and real-world experience including ours. In addition, relapse can be seen not only in those who are downtitrated or discontinued medication but also in patients under treatment, leaving room for further improvement/development. New medications and/or dosing regimens tested in currently ongoing/planned clinical trials have potential to address JAKi-associated unmet needs in severe AA.
科研通智能强力驱动
Strongly Powered by AbleSci AI